862 related articles for article (PubMed ID: 29412111)
1. Efficacy of P2Y12 Receptor Blockers After Myocardial Infarction and Genetic Variability of their Metabolic Pathways.
Máchal J; Hlinomaz O
Curr Vasc Pharmacol; 2019; 17(1):35-40. PubMed ID: 29412111
[TBL] [Abstract][Full Text] [Related]
2. Reversibility of platelet P2Y12 inhibition by platelet supplementation: ex vivo and in vitro comparisons of prasugrel, clopidogrel and ticagrelor.
Bertling A; Fender AC; Schüngel L; Rumpf M; Mergemeier K; Geißler G; Sibrowski W; Kelsch R; Waltenberger J; Jakubowski JA; Kehrel BE
J Thromb Haemost; 2018 Jun; 16(6):1089-1098. PubMed ID: 29582544
[TBL] [Abstract][Full Text] [Related]
3. Third generation P2Y12 antagonists inhibit platelet aggregation more effectively than clopidogrel in a myocardial infarction registry.
Olivier CB; Diehl P; Schnabel K; Weik P; Zhou Q; Bode C; Moser M
Thromb Haemost; 2014 Feb; 111(2):266-72. PubMed ID: 24172891
[TBL] [Abstract][Full Text] [Related]
4. Response variability to P2Y12 receptor inhibitors: expectations and reality.
Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
[TBL] [Abstract][Full Text] [Related]
5. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
[TBL] [Abstract][Full Text] [Related]
6. Translation of experimental cardioprotective capability of P2Y
Hjortbak MV; Olesen KKW; Seefeldt JM; Lassen TR; Jensen RV; Perkins A; Dodd M; Clayton T; Yellon D; Hausenloy DJ; Bøtker HE;
Basic Res Cardiol; 2021 May; 116(1):36. PubMed ID: 34037861
[TBL] [Abstract][Full Text] [Related]
7. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.
Ariotti S; Ortega-Paz L; van Leeuwen M; Brugaletta S; Leonardi S; Akkerhuis KM; Rimoldi SF; Janssens G; Gianni U; van den Berge JC; Karagiannis A; Windecker S; Valgimigli M;
JACC Cardiovasc Interv; 2018 Aug; 11(16):1576-1586. PubMed ID: 29805112
[TBL] [Abstract][Full Text] [Related]
8. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
[TBL] [Abstract][Full Text] [Related]
9. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
[TBL] [Abstract][Full Text] [Related]
10. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
11. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
Jiang M; You JH
Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
[TBL] [Abstract][Full Text] [Related]
12. Diabetes and CYP2C19 Polymorphism Synergistically Impair the Antiplatelet Activity of Clopidogrel Compared With Ticagrelor in Percutaneous Coronary Intervention-treated Acute Coronary Syndrome Patients.
Mohareb MW; AbdElghany M; Zaki HF; El-Abhar HS
J Cardiovasc Pharmacol; 2020 Oct; 76(4):478-488. PubMed ID: 32675750
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis.
Wang Z; Zhou DY; Su Y; Si LY; Xu Q
BMC Cardiovasc Disord; 2020 Mar; 20(1):130. PubMed ID: 32164560
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials.
Galli M; Benenati S; Franchi F; Rollini F; Capodanno D; Biondi-Zoccai G; Vescovo GM; Cavallari LH; Bikdeli B; Ten Berg J; Mehran R; Gibson CM; Crea F; Pereira NL; Sibbing D; Angiolillo DJ
Eur Heart J; 2022 Mar; 43(10):959-967. PubMed ID: 34918066
[TBL] [Abstract][Full Text] [Related]
15. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
[TBL] [Abstract][Full Text] [Related]
16. Intensified P2Y12 inhibition for high-on treatment platelet reactivity.
Mshelbwala FS; Hugenberg DW; Kreutz RP
J Thromb Thrombolysis; 2020 Oct; 50(3):619-627. PubMed ID: 32152791
[TBL] [Abstract][Full Text] [Related]
17. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.
Wen M; Li Y; Qu X; Zhu Y; Tian L; Shen Z; Yang X; Shi X
BMC Cardiovasc Disord; 2020 Oct; 20(1):430. PubMed ID: 33004000
[TBL] [Abstract][Full Text] [Related]
18. Genetics of platelet inhibitor treatment.
Trenk D; Hochholzer W
Br J Clin Pharmacol; 2014 Apr; 77(4):642-53. PubMed ID: 23981082
[TBL] [Abstract][Full Text] [Related]
19. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score.
Angiolillo DJ; Capodanno D; Danchin N; Simon T; Bergmeijer TO; Ten Berg JM; Sibbing D; Price MJ
JACC Cardiovasc Interv; 2020 Mar; 13(5):606-617. PubMed ID: 32139218
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
